AEON (AEON) CLO adds large stock awards and converts prior RSUs
Rhea-AI Filing Summary
AEON Biopharma, Inc. reported that executive Wilson Alexander Blair, its CLO, CSO and Corporate Secretary, acquired Class A common stock through equity compensation awards rather than open-market purchases.
On February 17, 2026, he received an award of 862,500 restricted stock units, vesting in substantially equal installments on each of the first four anniversaries of the grant date, subject to continued service. On March 4, 2026, 1,316,872 previously cash-settled restricted stock units granted on May 21, 2025 were modified to be settled in stock instead of cash, with the original four-year vesting schedule maintained. Both transactions were reported at a price of $0.00 per share and are classified as direct ownership, bringing Blair’s total directly held Class A shares to 2,183,005 after the March 4 transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 1,316,872 | $0.00 | -- |
| Grant/Award | Class A Common Stock | 862,500 | $0.00 | -- |
Footnotes (1)
- Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the "Grant Date") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.